ĐÁNH GIÁ KẾT QUẢ BƯỚC ĐẦU PHỐI HỢP TRA AZARGA VÀ TIÊM BEVACIZUMAB NỘI NHÃN TRONG ĐIỀU TRỊ PHÙ HOÀNG ĐIỂM DO ĐÁI THÁO ĐƯỜNG

Abstract

Purpose: To assess the first result of adjuvant topical azarga with intravitreal bevacizumab (IVB) injection on anatomy and function in eyes affected with diabetic macular edema (DME). Methods: Thirty patients with bilateral DME who were treatment-naive were enrolled. Enrolled patients received a treatment plan of topical azarga twice daily in the interventional eye. Three monthly bilateral IVB injections 1.25 mg/0.05 mL were also planned. Baseline central macular thickness (CMT) and central macula volume (CMV) were measured by spectral-domain optical coherence tomography (SD-OCT), clinical information such as best corrected visual acuity (BCVA) and intraocular pressure (IOP) were collected at enrollment and one month after the third injection. Results: Thirty patients with DME were included. BCVA, CMT and CMV improved and normal IOP in both eyes. In repeated measures ANOVA analysis, There are many differences of improvement in anatomic and functional results between two groups, but the difference of improvement the CMT were significant in the interventional eye. Conclusion: Our study proved that first result of adjuvant topical azarga in combination with IVB is more effective than IVB alone  with improvement in anatomy (central macular thickness) in eyes with DME. This study also suggested that improvement in central macular volume and in function (visual acuity, intraocular pressure) of adjuvant topical azarga in combination with IVB will be obvious the following treatment months.